CSC
PRLD icon

Caldwell Sutter Capital’s Prelude Therapeutics PRLD Stock Holding History

Caldwell Sutter Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.42K Sell
1,000
-1,000
-50% -$2.62K ﹤0.01% 697
2025
Q4 		$5.8K Buy
+2,000
New +$3.38K ﹤0.01% 616

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Caldwell Sutter Capital's PRLD Position: Q1 2026 in Review

Caldwell Sutter Capital reduced its Prelude Therapeutics (PRLD) stake by 50% in Q1 2026, selling an estimated $2.62K and leaving 1,000 shares worth $3.42K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Caldwell Sutter Capital first reported a position in PRLD in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.8K in Q4 2025. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Caldwell Sutter Capital held 1,000 shares of Prelude Therapeutics worth $3.42K as of Q1 2026.
  • Caldwell Sutter Capital sold 1,000 Prelude Therapeutics shares in Q1 2026, an estimated $2.62K.
  • Prelude Therapeutics made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q1 2026, its #697 holding.
  • Caldwell Sutter Capital first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Caldwell Sutter Capital's Prelude Therapeutics position peaked at $5.8K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Caldwell Sutter Capital's 13F filing for Q1 2026, filed 6 May 2026.